Editorial: Advances in the treatment of chronic myeloid leukemia

• Ahmet Emre Eşkazan,
• Chung H. Kok,
• Chung H. Kok,
• Chung H. Kok,
• David Yeung,
• David Yeung,
• David Yeung,
• David Yeung,
• Jignesh Dalal,
• Jignesh Dalal,
• Mario Tiribelli,
• Mario Tiribelli

Affiliations

Ahmet Emre Eşkazan

Division of Hematology, Department of Internal Medicine, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul, Türkiye

Chung H. Kok

Precision Cancer Medicine Theme, South Australian Health & Medical Research Institute (SAHMRI), Adelaide, SA, Australia

Chung H. Kok

Adelaide Medical School, University of Adelaide, Adelaide, SA, Australia

Chung H. Kok

Centre for Cancer Biology, University of South Australia, Adelaide, SA, Australia

David Yeung

Precision Cancer Medicine Theme, South Australian Health & Medical Research Institute (SAHMRI), Adelaide, SA, Australia

David Yeung

Adelaide Medical School, University of Adelaide, Adelaide, SA, Australia

David Yeung

Centre for Cancer Biology, University of South Australia, Adelaide, SA, Australia

David Yeung

Department of Haematology, Royal Adelaide Hospital and SA Pathology, Adelaide, SA, Australia

Jignesh Dalal

Division of Hematology and Bone Marrow Transplant, Rainbow Babies and Children’s Hospital, OH, United States

Jignesh Dalal

Case Western Reserve University, Cleveland, OH, United States

Mario Tiribelli

Division of Hematology and Bone Marrow Transplant, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC) – Udine Hospital, Udine, Italy

Mario Tiribelli

Department of Medicine, University of Udine, Udine, Italy